Wednesday, July 26, 2017
 
 
Company News: Page (1) of 1 - 01/02/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

(January 02, 2017)

FIT Biotech Oy

Company release January 2, 2017 at 17.30 pm EET

FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

On September 26, 2016, the Board of Directors of FIT Biotech Oy (hereinafter also the "Company") decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 12,480,000 between the Company and Bracknor Investment.


The Company's Board of Directors has today decided to withdraw a third tranche of EUR 250,000 included in the Programme and to issue to Bracknor a total of 250 Convertible Notes and 3,387,534 Warrants, which entitle to subscribe for the Company's K shares in accordance with the Terms and Conditions of the Convertible Notes and the Warrants.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: [email protected]
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • Global Neuropsychiatric Disorders And Treatment Market Is Expected To Grow At A CAGR Of 6.2% During Forecast 2023
  • Urology Devices Global Market - Forecast to 2023
  • ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval
  • Wound Closure and Advanced Wound Care Global Market Forecast To 2023
  • Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

    Cancer
  • Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
  • Asia-Pacific Immunodiagnostics Analyzers and Reagents Market 2021: A 17-Country Analysis--Supplier Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review
  • Varian to Showcase Latest Radiotherapy and Radiosurgery Technologies and Software at AAPM 2017
  • American Brain Tumor Association's Annual Patient and Family Conference to Address Physical and Cognitive Symptoms and Side Effects
  • St. Jude Children's Research Hospital®, ALSAC Announce Chairs of Boards of Directors and Governors
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines